Diagnosis for COVID-19: current status and future prospects

Expert Rev Mol Diagn. 2021 Mar;21(3):269-288. doi: 10.1080/14737159.2021.1894930. Epub 2021 Mar 7.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19), a respiratory illness caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had its first detection in December 2019 in Wuhan (China) and spread across the world. In March 2020, the World Health Organization (WHO) declared COVID-19 a pandemic disease. The utilization of prompt and accurate molecular diagnosis of SARS-CoV-2 virus, isolating the infected patients, and treating them are the keys to managing this unprecedented pandemic. International travel acted as a catalyst for the widespread transmission of the virus.Areas covered: This review discusses phenotype, structural, and molecular evolution of recognition elements and primers, its detection in the laboratory, and at point of care. Further, market analysis of commercial products and their performance are also evaluated, providing new ways to confront the ongoing global public health emergency.Expert commentary: The outbreak for COVID-19 created mammoth chaos in the healthcare sector, and still, day by day, new epicenters for the outbreak are being reported. Emphasis should be placed on developing more effective, rapid, and early diagnostic devices. The testing laboratories should invest more in clinically relevant multiplexed and scalable detection tools to fight against a pandemic like this where massive demand for testing exists.

Keywords: Biosensing; COVID-19; SARS-CoV-2; diagnosis; point of care.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Biomarkers
  • COVID-19 / diagnosis*
  • COVID-19 / epidemiology
  • COVID-19 / transmission
  • COVID-19 / virology*
  • Disease Management
  • Evolution, Molecular
  • Humans
  • Molecular Diagnostic Techniques / methods
  • Molecular Diagnostic Techniques / standards
  • Nucleic Acid Amplification Techniques
  • Pandemics
  • Point-of-Care Testing
  • RNA, Viral
  • SARS-CoV-2 / physiology*

Substances

  • Biomarkers
  • RNA, Viral

Grants and funding

This manuscript has been supported by research support from the National Science Foundation (NSF) Rapid (2027890) and NSF CAREER (1942487).